Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

China

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Phase

Safety & dosing

Sponsor

Tongji Hospital

Collaborators

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Women's Hospital School Of Medicine Zhejiang University

Enrollment target

~40 participants

Started

May 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 45 Years

Sex

Female only

Last updated November 2024